ABVC BioPharma Expands Asian Market Presence with BioKey's Cancer and Immunity Supplement

ABVC BioPharma, Inc. announced its participation in BioLive’s Health Talk Event, showcasing BioKey’s Maitake BLEX 404 Dietary Supplement designed for cancer combination treatment and immunity enhancement. The event highlighted the company's penetration into the Asian market, driven by increasing orders from healthcare professionals and patients recognizing the product's potential to improve cancer treatment effectiveness and boost immune systems. This surge in demand presents a promising revenue opportunity, aligning with ABVC's growth strategy and vision to provide advanced healthcare solutions globally.

Uttam Patil, Ph.D., CEO of ABVC, emphasized the strong demand in Asia, noting that it reinforces the company's long-term growth and market expansion efforts. BioKey, a wholly owned subsidiary, is strategically positioned in Silicon Valley to leverage AI advancements, drawing inspiration from NVIDIA Corporation’s innovative projects to enhance research and development. Initiatives include generative AI for drug discovery, similar to NVIDIA’s BioNeMo framework, to accelerate the design of novel drug candidates and streamline early-stage discovery processes.

Additionally, BioKey is implementing GPU-accelerated genomic workflows using platforms like NVIDIA Clara Parabricks to reduce genomic data analysis time and expedite therapy target identification. The company is investing in AI models for advanced protein structure prediction and integrating AI into laboratory automation to improve efficiency and accuracy in drug validation. These AI-driven strategies position BioKey to advance biopharmaceutical innovations, capitalizing on collaborations with leading tech and biotech entities.

The global dietary supplements market, valued at USD 152.3 billion in 2022, is projected to reach USD 269.5 billion by 2030, with an 8.5% compound annual growth rate, as reported by Vantage Market Research. Similarly, the immunity booster supplement market, valued at approximately USD 27.19 billion in 2023, is expected to grow to around USD 75.35 billion by 2033. ABVC's focus on expanding its product portfolio and entering new markets addresses this growing demand, reinforcing its commitment to innovative therapies that integrate cancer treatment with immunity-boosting methods to enhance patients' quality of life worldwide.